TOI trades 37.9% below Wall Street's consensus target of $7.50.
Last 12 months price action with 12-month analyst target path
The base valuation assumes TOI achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 5 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of July 7, 2026, The Oncology Institute, Inc. (TOI) has a Wall Street consensus price target of $7.50, based on estimates from 5 covering analysts. With the stock currently trading at $5.44, this represents a potential upside of +37.9%. The company has a market capitalization of $5.54B.
Analyst price targets range from a low of $7.00 to a high of $8.00, representing a 13% spread in expectations. The median target of $7.50 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 5 analysts rating the stock as a Buy or Strong Buy,0 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, TOI trades at a trailing P/E of -10.1x. Analysts expect EPS to grow -251.3% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
AIOTPowerFleet, Inc. | $588M | $4.38 | $7.00 | +59.8% | Buy | — | 5 |
ONCOOnconetix, Inc. | $691381 | $1.10 | — | — | — | — | — |
USPHU.S. Physical Therapy, Inc. | $1.1B | $73.38 | $96.00 | +30.8% | Buy | 26.2x | 13 |
OPCHOption Care Health, Inc. | $3.3B | $21.36 | $31.22 | +46.2% | Buy | 11.6x | 14 |
ADUSAddus HomeCare Corporation | $2.0B | $105.73 | $122.00 | +15.4% | Buy | 15.1x | 16 |
AMSFAMERISAFE, Inc. | $651M | $34.65 | $44.50 | +28.4% | Buy | 16.5x | 6 |
MCKMcKesson Corporation | $94.3B | $784.23 | $994.86 | +26.9% | Buy | 17.7x | 31 |
CAHCardinal Health, Inc. | $55.9B | $237.52 | $253.38 | +6.7% | Buy | 22.1x | 33 |
VEEVVeeva Systems Inc. | $31.2B | $192.01 | $235.38 | +22.6% | Buy | 21.2x | 43 |
DOCSDoximity, Inc. | $4.3B | $22.86 | $29.47 | +28.9% | Hold | 15.9x | 23 |
Quick answers to the most common questions about buying TOI stock.
The consensus Wall Street price target for TOI is $7.5, representing 37.9% upside from the current price of $5.44. With 5 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
TOI has a consensus rating of "Buy" based on 5 Wall Street analysts. The rating breakdown is predominantly bullish, with 5 Buy/Strong Buy ratings. The consensus 12-month price target of $7.5 implies 37.9% upside from current levels.
TOI's current price is $5.44 with a consensus target of $7.5 (37.9% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $8 for TOI, while the most conservative target is $7. The consensus of $7.5 represents the median expectation. These targets typically reflect 12-month expectations.
TOI is moderately covered, with 5 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 5 have Buy ratings, 0 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month TOI stock forecast based on 5 Wall Street analysts shows a consensus price target of $7.5, with estimates ranging from $7 (bear case) to $8 (bull case). The median consensus rating is "Buy".
Wall Street analysts are very optimistic on TOI, with a "Buy" consensus rating and $7.5 price target (37.9% upside). 5 of 5 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
TOI analyst price targets range from $7 to $8, a 13% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $7.5 consensus represents the middle ground.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.